Text-Messaging (TM) vs Text-Messaging Plus Patient Navigation: Uptake-Total
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.439 | 0.434 | 0.444 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.44 | 0.434 | 0.445 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.000729 | -0.00834 | 0.00688 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.998 | 0.981 | 1.02 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.997 | 0.967 | 1.03 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Text-Messaging (TM) than on Text-Messaging Plus Patient Navigation | 1,370 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Text-Messaging (TM) | Population health management intervention that analyzes electronic health record data to automatically identify participants who are eligible for the COVID-19 vaccine and proactively reach those participants for vaccine scheduling. This is a bi-directional text messaging system.~Text-Messaging (TM): Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine. | 14,308 | 32,594 | OG000 | ClinicalTrials.gov |
| Group 2 | Text-Messaging Plus Patient Navigation | Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD vaccination.~Text-Messaging (TM): Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine.~Patient Navigation (PN): Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy. | 14,381 | 32,706 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Uptake-Total | ClinicalTrials.gov |
| Description | Proportion of patients who receive a COVID-19 vaccine out of the total patient population | ClinicalTrials.gov |
| Time frame | 12 months | ClinicalTrials.gov |
| Population | Proportion of patients who receive a COVID-19 vaccine out of the total patient population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers | ClinicalTrials.gov |
| NCT number | NCT04939519 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Covid19 | ClinicalTrials.gov |
| Interventions | Text-Messaging (TM), Patient Navigation (PN) | ClinicalTrials.gov |
| Lead sponsor | University of Utah | ClinicalTrials.gov |
| Results first posted | 2025-12-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04939519?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.